FDA approves another Alzheimer's drug that can modestly slow disease

  • 📰 fox13seattle
  • ⏱ Reading Time:
  • 19 sec. here
  • 4 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 59%

Health News

News,Us

The Food and Drug Administration (FDA) approved a second Alzheimer's drug that can modestly slow the disease. Eli Lilly's Kisunla IV infusion drug showed a 22% decrease in cognitive decline.

U.S. officials have approved another Alzheimer’s drug that can modestly slow the disease, providing a new option for patients in the early stages of the incurable, memory-destroying ailment.The Food and Drug Administration approved Eli Lilly’s Kisunla on Tuesday for mild or early cases of dementia caused by Alzheimer’s. It’s only the second drug that’s been convincingly shown to delay cognitive decline in patients, following last year’s approval of a similar drug from Japanese drugmaker Eisai.

The FDA approved Kisunla, known chemically as donanemab, based on results from an 18-month study in which patients given getting the treatment declined about 22% more slowly in terms of memory and cognitive ability than those who received a dummy infusion.The main safety issue was brain swelling and bleeding, a problem common to all plaque-targeting drugs.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 328. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

High Confidence Alzheimer's Drug Donanemab Will Get FDA Panel NodAn FDA advisory committee will meet June 10 to offer its opinion on whether the agency should greenlight donanemab for Alzheimer's disease.
Source: Medscape - 🏆 386. / 55 Read more »

FDA analysis raises no major concerns about Eli Lilly Alzheimer's drugAn FDA analysis of trial data for Eli Lilly's experimental Alzheimer's drug donanemab released on Thursday revealed no red flags, but raised questions about safety of the treatment for patients with early-stage disease.
Source: KSLcom - 🏆 549. / 51 Read more »

Alzheimer's drug that can slow disease gets backing from FDA advisersFederal health advisers have endorsed a closely watched Alzheimer’s drug from Eli Lilly for people with mild dementia. The FDA will make the final decision on approval later this year. If the agency agrees with its advisers, the drug would only be the second Alzheimer’s drug clearly shown to slow cognitive decline due to Alzheimer’s.
Source: AP - 🏆 728. / 51 Read more »

Alzheimer's drug that can slow disease gets backing from FDA advisersFederal health advisers have endorsed a closely watched Alzheimer’s drug from Eli Lilly for people with mild dementia.
Source: ksatnews - 🏆 442. / 53 Read more »